Phenotypic and Genetic Characterization of Antimicrobial Profiles of Helicobacter pylori Strains in Cuba by Llanes, Rafael et al.
©INTERNATIONAL CENTRE FOR DIARRHOEAL
DISEASE RESEARCH, BANGLADESH
J HEALTH POPUL NUTR 2010 Apr;28(2):124-129
ISSN 1606-0997 | $ 5.00+0.20
Correspondence and reprint requests should be 
addressed to: 
Dr. Rafael Llanes
Institute Pedro Kouri 
Autopista Novia Mediodía km6
PO Box 601
Marianao 13, Havana
Cuba
Email: llanes@ipk.sld.cu
Fax: 537 204 6051
Phenotypic and Genetic Characterization of Antimicrobial 
Profiles of Helicobacter pylori Strains in Cuba
Rafael Llanes1, Claudia Soria1, Shigeo Nagashima2, Nobumichi Kobayashi2, Angela Gala1, Daymi 
Guzmán1, Onelkis Feliciano1, Lidunka Valdés1, Oderay Gutiérrez1, Heriberto Fernández3, 
Alina Llop1, and Akihiro Wada4
1Microbiology, Clinical and Epidemiology Branch, Institute Pedro Kouri, Havana, Cuba, 2 Department of Hygiene, Sapporo 
Medical University, Sapporo, Japan, 3Department of Microbiology, Universidad Austral de Chile, Valdivia, Chile, and 
4 Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University, Japan
ABSTRACT
The study evaluated the antibiotic resistance patterns of Helicobacter pylori strains against metronidazole and 
clarithromycin in a hospital in Havana, Cuba. Eighty-five percent, 22.5%, and 10% of 40 H. pylori strains 
investigated were resistant to metronidazole, ciprofloxacin, and clarithromycin respectively but all were 
susceptible to amoxicillin and tetracycline. RdxA truncation was found only in metronidazole-resistant 
strains. In such strains, reported are eight and two novel mutations in the rdxA and frxA genes respectively. 
Two-point mutations in the 23S rRNA genes of clarithromycin-resistant strains were detected. A high preva-
lence of metronidazole resistance was found in Cuban H. pylori strains. Mutations in the rdxA gene may 
contribute more significantly than frxA gene to the high level of resistance to metronidazole. This study 
supports the need to continue monitoring the antibiotic susceptibility in H. pylori in Cuba to guide the 
treatment of such infection.
Key words: Antibiotic resistance; Gene mutations; Helicobacter pylori; Cuba
INTRODUCTION
Helicobacter pylori is responsible for chronic gastritis, 
peptic ulcer disease, and gastric mucosa-associated 
lymphoid tissue lymphoma and is a major risk fac-
tor for the development of gastric adenocarcino-
ma (1). Eradication of such bacteria by treatment 
with two antimicrobial agents—clarithromycin 
(CLA)  and  amoxicillin  (AMX)  or  metronidazole 
(MTZ)—and a proton pump inhibitor is recom-
mended by various consensus groups (2). 
Investigation on the susceptibility of H. pylori to an-
tibiotics is one of the main factors associated with 
successful eradication therapy (3).
MTZ resistance in H. pylori is caused by null 
mutations in the rdxA gene and less frequently by 
mutations in frxA and fdxB genes. Resistance to 
CLA is associated with point mutations in the 23S 
rRNA gene (2).
The prevalence of H. pylori-resistant strains is high 
in naive patients and even higher in patients suffer-
ing unsuccessful eradication therapy (4).
In Cuba, the prevalence of H. pylori-associated in-
fection among children and adults is 42.4% and 
82.7% respectively (5); however, no information 
is available on antimicrobial susceptibility to com-
monly-used drugs for the treatment of infection 
due to H. pylori. This study was conducted to evalu-
ate (a) resistance of five antimicrobial agents and 
(b) genetic basis for MTZ and CLA resistance in H. 
pylori strains from a hospital in Havana city, Cuba. 
The study also investigated the demographic and 
clinical factors associated with antibiotic resist-
ance.
MATERIALS AND METHODS
Patients, gastric biopsies, and culture
In total, 70 consecutive patients aged 19-68 years 
were enrolled, and of them, 42 were male and 28 
were female. They attended the hospital of the Insti-
tute Pedro Kouri, Havana, Cuba, for upper gastroin-Llanes R et al. Antimicrobial resistance of H. pylori
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testinal endoscopy during the last four months of 
2005. Of the patients, 51 had non-ulcer dyspepsia 
(NUD), and 19 had peptic ulcer (PU).
A gastric biopsy specimen obtained from the an-
trum of each patient was cultured onto selective 
Columbia agar plates (Oxoid, UK), with 10% sheep-
blood and Dent supplement (Oxoid). The plates 
were incubated at 37 °C in a micro-aerobic atmos-
phere (Campybag, Oxoid) for 3-5 days. A culture 
was considered positive if typical H. pylori colonies 
were observed and the microorganisms grown were 
positive in catalase, oxidase and urease tests (5).
Susceptibility testing
The minimum inhibitory concentrations (MICs) 
were determined for MTZ, CLA, AMX, cipro-
floxacin (CIP), and tetracycline (TET) by the E-test 
method (AB Biodisk, Solna, Sweden) as described 
by the Clinical and Laboratory Standards Institute 
(CLSI). Mueller Hinton agar (Oxoid), with 5% of 
aged sheep-blood, was used as culture medium for 
determining antibiotic susceptibility (6). All tests 
were performed thrice, and H. pylori ATCC 43504 
was used as a control strain.
Susceptibility to CLA was interpreted according to 
the guidelines of the CLSI (6). Since the CLSI has 
not designated breakpoints for other antimicrobi-
als in H. pylori, the following MIC values were used 
in defining resistance: MTZ ≥8 mg/L, AMX and CIP 
≥1 mg/L, and TET ≥2 mg/L (7). 
PCR and DNA sequence analysis 
Bacterial genomic DNA was extracted using the 
DNeasy tissue kit (QIAGEN, Japan). Resistant 
genes—rdxA, frxA, and 23S rRNA—were amplified 
using PCR with specific primers as previously de-
scribed (8,9). Amplified DNA was purified using 
Wizard-SV gel and PCR Clean-Up System (Promega, 
USA) and was then sequenced in both directions 
using the ABI PRISM 3100 automatic sequencer 
(Applied Biosystems, USA). For identification of 
ribosomal mutations, sequences were compared 
with the genomic sequences of H. pylori reference 
strains J99 and 26695 (8). Comparisons were done 
using the software available over the Internet at the 
National Center for Biotechnology Information 
website (http://www.ncbi.nlm.nih.gov), and multi-
ple alignments were performed using the Genetyx-
Mac software (version 11.2) (Genetyx Corporation, 
Japan) (10).
Statistical analysis
Statistical analysis was carried out with the SPSS 
software for Windows (version 11.0) (Chicago, 
USA). The chi-square and Fischer’s tests were used 
for determining the differences between patterns of 
resistance by age-group, sex, and clinical features. 
The p values of <0.05 were regarded as statistically 
significant. 
Ethics 
The present study was conducted in accordance 
with the Declaration of Helsinki and the ethical 
committee of the Institute Pedro Kouri. Written 
informed consent was obtained from each subject 
to participate in the study. The gastric mucosa bi-
opsy for diagnosis of H. pylori-associated infection 
is part of the routine management in patients with 
dyspepsia and peptic ulcer. 
RESULTS
Antimicrobial susceptibility 
Forty-six (65.7%) of the 70 enrolled patients were 
positive for H. pylori by culture. Of the 46 strains, 
40 were available for antimicrobial susceptibility 
testing with 67.5% (27 of 40) and 32.5% (13 of 40) 
of the strains from non-ulcer dyspepsia and peptic 
ulcer patients respectively. 
Eighty-five percent, 22.5%, and 10% of the 40 H. 
pylori strains investigated were resistant to MTZ, 
CIP, and CLA respectively but all were susceptible 
to AMX and TET. The MIC50 and MIC90 values for 
MTZ were 256 mg/L. In the case of CIP, the MIC50 
was 0.125 mg/L, and the MIC90 was 32 mg/L (Table 
1).
Our study revealed multiple antibiotic resistance 
patterns in 25% (10/40) of H. pylori strains inves-
tigated. Combined resistance to MTZ-CIP (6/10 
strains) was most frequently found, followed by 
patterns—MTZ-CLA and MTZ-CIP-CLA, with two 
strains each.
Antimicrobial susceptibilities of the strains col-
lected from patients with PU and NUD, males and 
females and stratified in age-groups below and 
above 40 years were compared, and no significant 
difference (p>0.05) in antimicrobial resistance was 
observed among these groups (Table 2). 
Characterization of rdxA and frxA genes of 
MTZ-sensitive and resistant strains
A MTZ-sensitive strain (#56) exhibited amino acid 
substitution (missense mutation). In the case of 
MTZ-resistant strains, one had a missense muta-
tion (#191); seven demonstrated amino acid subs- 
titutions (#84C, #93, #113, #114, #127, #227, 
and #230); two had nonsense mutations (#81 and 
#117); and three others (#67, #84A, and #146) 
showed both nonsense mutations and amino acid Llanes R et al. Antimicrobial resistance of H. pylori
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Table 1. Susceptibility of 40 Helicobacter pylori Cuban strains to five antibiotics
Antimicrobial
  Antimicrobial susceptibility
MIC values (mg/L)
Susceptible Resistant 
No.         % No       %   MIC range   MIC50   MIC90
Amoxicillin 40          100  -      0.016-1   0.016   0.03
Clarithromycin 36           90  4        10  0.016-256   0.016  0.125
Ciprofloxacin 31          77.5  9       22.5   0.016-32   0.125    32
Metronidazole 6             15 34       85     1-256     256   256
Tetracycline 40          100   -    0.016-1     0.06   0.25
MIC=Minimum inhibitory concentration
Table 2. Resistance of 40 Helicobacter pylori Cuban strains to three antibiotics by sex, age, and 
clinical features of patients
Antimicrobial 
      No. (%) of resistant strains in patients
      PU       NUD  Male Female <40 years >40 years
  (n=13)     (n=27) (n=22) (n=18) ( n=13) (n=27)
Metronidazole 11 (84.6)   23 (85.2) 21 (95.4) 13 (72.2) 11 (84.6) 23 (85.2)
p=0.67 p=0.10 p=0.67
Clarithromycin 1 (7.7) 3 (11.1) 3 (13.6) 1 (5.6)         - 4 (14.8)
p=0.82 p=0.75 p=0.36
Ciprofloxacin 2 (15.4) 7 (25.9) 5 (22.7) 4 (22.2) 2 (15.4) 7 (25.9)
p=0.73 p=0.73 p=0.73
NUD=Non-ulcer dyspepsia; PU=Peptic ulcer
substitutions that resulted in a truncated RdxA pro-
tein at positions 35, 75, 139, and 211. One strain 
(#17) remained unchanged for the rdxA gene (Table 
3). 
With a few exceptions, the open reading frame 
for the frxA gene was disrupted by a deletion of a 
nucleotide (nt) at position 54 and 98, and in the 
resistant strain #146 by a nt insertion at position 
248. These events led to the occurrence of a stop 
codon at positions corresponding to amino acids 
39, 74, or 83. In resistant strains #113 and #114, 
some point mutations were observed (Table 3). 
Analysis of mutations in CLA-resistant and 
susceptible strains
Of the three resistant strains investigated, two 
(66.7%) harboured 23S rDNA mutations at position 
A2142G (n=1), or in both, A2142 and A2143 posi-
tions (n=1). These two strains exhibited high-level 
resistance to CLA (MIC >256 mg/L). The remaining 
three strains (two susceptible and a CLA-resistant 
one with an MIC value of 8 mg/L) did not show 
such alterations at the conserved V domain of genes-
encoding 23S rRNA (data not shown).
DISCUSSION
In patients undergoing endoscopy, therapy should 
be tailored based on antimicrobial susceptibility 
data (11).
Resistance to antimicrobials, as detected in culture, 
is of particular concern with H. pylori as a major 
cause of eradication failure. Resistance to MTZ is the 
most common type of resistance in this pathogen 
(3). The high frequency of resistance to this drug 
in H. pylori strains studied might be due to its fre-
quent use for the treatment of intestinal parasites 
and gynaecological disorders. MTZ also represents 
the third most-used antibiotic by Cuban patients 
attending the primary healthcare system (12).  
It is noteworthy that the mutation Ala (37) →Val, 
detected in a MTZ-susceptible strain, was different 
from those observed in MTZ-resistant ones, and so 
could not be essential for resistance. Some muta-
tions detected in the rdxA gene from the resistant 
strains—Arg(10)→Ile; Arg(16)→Cys; Arg(16)→His; 
His(97)→Thr;  Ser(81)→Leu—have  been  described 
previously (8,9,13).  
An interesting finding in MTZ-resistant strains in 
our study was the detection of several mutations 
not previously described in the literature in rdxA 
gene: [Glu (139)→Stop codon; Pro(106)→Ser;   
Val(111)→Ala; Thr(208)→Ala; Asn(14)→Thr; Glu 
(171)→Lys; Met(56)→Val; Arg(191)→Lys] and in 
frxA gene: [Glu(199)→Stop codon; Stop codon at 
position 83], which might be associated with resist-
ance.Llanes R et al. Antimicrobial resistance of H. pylori
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Some reports established that inactivation of frxA 
without mutations in rdxA could not cause MTZ re-
sistance (8,13). Our results suggest that alterations 
of frxA alone produced resistance, e.g. strain 17. 
However, as the frxA mutations were also observed 
in MTZ-susceptible strains, we conclude that these 
are unlikely to contribute to the MTZ resistance of 
these strains.
CLA is the most powerful antibiotic currently used 
for the treatment of H. pylori. Resistance to this 
antibiotic considerably reduces the success rate of 
standard triple therapies (14). The percentage of 
CLA resistance found in this study and the type of 
mutations in the 23S rRNA gene are similar to re-
ports from the USA, Japan, and Bulgaria (2).      
In the current investigation, a moderately-resistant 
CLA strain lacked any mutation in the analyzed re-
gion of the 23S rRNA gene, and the basis for such 
resistance remains undetermined. It suggests that 
other undetected 23S rRNA mutations may be in-
volved in resistance, which has been reported else-
where (15). As H. pylori contains two copies of 23S 
rRNA, sometimes it exhibits a heterozygous con-
dition in which one of the genes is mutated and 
the other remains normal. This genotype confers 
a CLA-resistant phenotype (15). In addition, a hete- 
rogeneous resistance pattern reflecting mixed in-
fections with susceptible and resistant populations 
to CLA and other antimicrobials has been observed 
in H. pylori isolates (16).
CLA has never been used for the treatment of H. 
pylori-associated infections in Cuba but other 
macrolides, such as erythromycin and azithro-
mycin, have been widely used in several infections 
in this country (17). Cross-resistance between CLA 
and other macrolides have been described before 
and may account for the observed resistance (14).
Combined resistance to MTZ and CLA may com-
promise the effectiveness of current triple therapy 
regimens for H. pylori-associated infections (16). 
Interestingly, our analysis of resistance patterns 
showed that strains with dual resistance to these 
drugs were relatively uncommon (10%) in the 
study population.
After treatment failures to commonly-used anti-H. 
pylori antibiotics, such as MTZ or CLA, quinolone-
based triple therapies have been proposed as rescue 
regimens (2). The prevalence of resistance to such 
antimicrobials has been determined in only a limi- 
ted number of studies (7,18). The mechanism of 
resistance to fluoroquinolones in H. pylori has been 
shown to be linked to mutations in the so-called 
quinolone resistance-determining region (QRDR) 
of the gyrA gene (18). In the present study, we did 
not investigate the mutations associated with such 
resistance. In future studies, it would be noticeable 
to perform the sequencing analysis of the QRDR re-
gion in fluoroquinolone-resistant strains. The high 
percentage of CIP resistance in the present study 
might be a consequence of its frequent use for the 
management of several infectious diseases in Cuba 
(12). 
In vitro resistance to AMX or TET appears to be rare 
among primary isolates of H. pylori (13) as, in our 
study, several investigations have shown a very 
marked susceptibility to these two drugs (2,5,14). 
However, it is necessary to mention that subse-
quent freezing of H. pylori strains at –80 °C can re-
sult in the loss of AMX-resistant phenotype (19).
The present current study was conducted to gather 
preliminary data on antimicrobial susceptibility of 
H. pylori strains from a hospital in Havana, Cuba. 
Consequently, they are not representative of all Cu-
ban population. The participating hospital centre 
serves only adult patients from a limited area.
In resume, we found a high frequency of MTZ and 
CIP resistance in H. pylori strains for the first time in 
Cuba. Mutations in the rdxA gene may contribute 
more significantly than frxA gene to the high-level 
MTZ resistance. The present investigation suggests 
the need for continuous monitoring of the antimi-
crobial susceptibility in H. pylori strains in Cuba.  
Public-health implications
Overall, the weight of evidence suggests that eradi-
cation of H. pylori will prevent the majority of gas-
tric cancers that are caused by gastric inflammation 
and many that are associated with gastric atrophy. 
Screening of population and treatment for infec-
tion due to H. pylori is an appealing strategy (20) as 
the aim is to prevent disease and its complications. 
The data on antimicrobial susceptibilities provided 
by the present study is critical to guide the clini-
cians on the effectiveness of treatment regimens. 
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